| SCHEDULE OF BUSINESS INTERESTS INTO REPORTABLE SEGMENTS |
SCHEDULE OF BUSINESS INTERESTS INTO REPORTABLE SEGMENTS
| Nine Months Ended September 30, 2022 | |
Trxade, Inc. | | |
CSP | | |
Integra | | |
Unallocated | | |
Total | |
| Revenue | |
$ | 4,001,670 | | |
$ | | |
$ | 3,949,772 | | |
$ | 62,787 | | |
$ | 8,919,312 | |
| Gross Profit | |
| 4,001,670 | | |
| ) | |
| (41,462 | ) | |
| 62,787 | | |
| 3,908,608 | |
| Segment Assets | |
| 1,853,474 | | |
| | |
| 454,783 | | |
| 2,111,177 | | |
| 4,689,261 | |
| Segment Profit (Loss ) | |
| 1,320,138 | | |
| ) | |
| (493,203 | ) | |
| (3,070,562 | ) | |
| (2,606,839 | ) |
| Cost of Sales | |
$ | - | | |
$ | | |
$ | 3,991,234 | | |
$ | - | | |
$ | 5,010,704 | |
| Nine Months Ended September 30, 2021 | |
Trxade, Inc. | | |
CSP | | |
Integra | | |
Unallocated | | |
Total | |
| Revenue | |
$ | 3,653,269 | | |
$ | | |
$ | 2,511,270 | | |
$ | 49,700 | | |
$ | 7,501,535 | |
| Gross Profit | |
| 3,652,015 | | |
| | |
| (319,104 | ) | |
| 49,362 | | |
| 3,505,743 | |
| Segment Assets | |
| 1,487,657 | | |
| ) | |
| 563,396 | | |
| 3,867,221 | | |
| 5,514,101 | |
| Segment Profit (Loss) | |
| 1,511,809 | | |
| ) | |
| (2,500,032 | ) | |
| (3,454,295 | ) | |
| (4,531,543 | ) |
| Cost of Sales | |
$ | 1,254 | | |
$ | | |
$ | 2,830,374 | | |
$ | 338 | | |
$ | 3,995,792 | |
|
SCHEDULE OF BUSINESS INTERESTS INTO REPORTABLE SEGMENTS
Year Ended December 31, 2021 | |
Trxade, Inc. | | |
Community Specialty Pharmacy, LLC | | |
Integra Pharma, LLC | | |
Unallocated | | |
Total | |
| Revenue | |
$ | 4,924,015 | | |
$ | | |
$ | 3,250,561 | | |
$ | 62,016 | | |
$ | 9,889,433 | |
| Gross Profit | |
$ | 4,921,084 | | |
$ | | |
$ | (393,582 | ) | |
$ | 61,678 | | |
$ | 4,745,965 | |
| Segment Assets | |
$ | 2,273,330 | | |
$ | ) | |
$ | 565,619 | | |
$ | 3,358,808 | | |
$ | 5,766,164 | |
| Segment Profit/Loss | |
$ | 1,977,938 | | |
$ | ) | |
$ | (2,749,028 | ) | |
$ | (4,416,230 | ) | |
$ | (5,315,883 | ) |
Year Ended December 31, 2020 | |
Trxade, Inc. | | |
Community Specialty Pharmacy, LLC | | |
Integra Pharma, LLC | | |
Unallocated | | |
Total | |
| Revenue | |
$ | 5,546,746 | | |
$ | | |
$ | 9,877,067 | | |
$ | 44,783 | | |
$ | 17,122,520 | |
| Gross Profit | |
$ | 5,546,746 | | |
| | |
| 8,374 | | |
$ | 44,431 | | |
$ | 5,707,322 | |
| Segment Assets | |
$ | 2,076,934 | | |
$ | ) | |
| 2,698,357 | | |
$ | 5,475,195 | | |
$ | 9,792,702 | |
| Segment Profit/Loss | |
$ | 3,309,128 | | |
$ | ) | |
$ | (531,092 | ) | |
$ | (4,413,660 | ) | |
$ | (2,536,051 | ) |
|